HHealthcare Read More Pfizer Stock Is A Race Between New Drugs And Old PatentsAugust 21, 2026 The medicines Pfizer has launched and acquired are arriving at close to the scale of the revenue its…
HHealthcare Read More Why Isn’t Eli Lilly Stock Trading At The Top Of Its Peer Group?August 18, 2026 The market seems to have its pharma giants ranked in a peculiar order, leaving one of the group’s…
HHealthcare Read More Eli Lilly Stock’s Next Climb Runs Through A Pill, Not Just An InjectionAugust 13, 2026 The case for more upside rests on its obesity pill, and what changed is not the drug but…
HHealthcare Read More The Signs Before Eli Lilly Stock Surged Were All On The RecordAugust 2, 2026 Eli Lilly stock ran on a story that was public and dated long before the price moved, and…
HHealthcare Read More Johnson & Johnson Is Becoming A Narrower Company Than You BoughtJuly 26, 2026 Management’s plain health care label has slipped out of the lead, and the business now on a separation…
HHealthcare Read More The Real Engine Behind Johnson & Johnson Stock’s Next ClimbJuly 21, 2026 While many investors focus on a slowdown in one business segment, they may be overlooking the remarkable growth…
HHealthcare Read More Everyone Is Watching Eli Lilly Stock’s New Drugs. Here Is the Metric That VanishedJune 18, 2026 Management once made manufacturing its top priority; now that the topic has gone quiet, it reveals just how…
HHealthcare Read More The Catch Hiding In Eli Lilly Stock’s Growth StoryJune 14, 2026 Eli Lilly’s obesity drug franchise is a juggernaut, but a surprisingly large share of its success relies on…
HHealthcare Read More Pfizer, YaoPharma sign $150M GLP-1 obesity drug collaborationDecember 9, 2025 Key Terms phase 1 medical Phase 1 is the first stage of testing…
AArtificial intelligence Read More Nasdaq Falls as Worries Mount on Jobs and AI ValuationsNovember 6, 2025 A slide in big tech shares led a broad selloff Thursday, spurred by weak economic data and renewed…